Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | NT5E | P21589 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131219 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL8373455 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL15472807 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL7753712 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL489384 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL24652562 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL278439 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL489378 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL22826758 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL6725298 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127452-A1 | NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF | APICORE US LLC (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127452-A1 | NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF | PRPF6, CYP2D6, ADH1A | ADORA2A 873/4885ADORA2B 577/4885CYP1A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.